NCT01527461

Brief Summary

The purpose of this study is to show that dogs are able to detect cancer in sweat samples. This potentially would be the base for developing a new efficient, non invasive and inexpensive diagnosis tool of lung cancer.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 27, 2012

Completed
5 days until next milestone

Study Start

First participant enrolled

February 1, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 7, 2012

Completed
Last Updated

June 4, 2013

Status Verified

June 1, 2013

First QC Date

January 27, 2012

Last Update Submit

June 2, 2013

Conditions

Keywords

lung neoplasmsdogssweatsmell

Outcome Measures

Primary Outcomes (1)

  • Number of patients with lung neoplasms

    Dogs ability to distinguish between COPD and lung cancer patients sweat samples

    one year

Study Arms (2)

Lung Cancer Patients

diagnosed lung cancer patients .

COPD Patients

COPD patients, not diagnosed with lung cancer.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The recruitment process will take place at the lung department of Sheba medical center. The participating physicians will enroll the patients and sing them on the consent form when they come for their regular appointments.

You may qualify if:

  • A diagnosis of lung cancer, regardless of histology.

You may not qualify if:

  • Inability to comply with study and/or follow up procedure.
  • Co morbidity of lung cancer and an additional malignancy combined.
  • Patients taking part in another clinical trial and receiving any treatment for it.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sheba Medical Center

Tel Hasomer, 52621, Israel

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

sweat samples

MeSH Terms

Conditions

Lung NeoplasmsAnosmia

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesOlfaction DisordersSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Nir Peled, MD PhD FCCP

    Sheba Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nir Peled, MD PhD FCCP

CONTACT

Michal Alumot, M.Sc,RD

CONTACT

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head, Thoracic Cancer Research and Detection Center,Tel Hashomer, Israel

Study Record Dates

First Submitted

January 27, 2012

First Posted

February 7, 2012

Study Start

February 1, 2012

Last Updated

June 4, 2013

Record last verified: 2013-06

Locations